Cytokine Production Associated with Smallpox Vaccine Responses

References

• Shchelkunov SN, Resenchuk SM, Totmenin AV, Blinov VM, Marennikova SS, Sandakhchiev LS. Comparison of the genetic maps of variola and vaccinia viruses. FEBS Letters 327(3), 321–324 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Langland JO, Kibler KV et al. Vaccinia virus vaccines: past, present and future. Antiviral Research 84(1), 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiology 2(1), 17–34 (2007).
   PubMed Web of Science ®Google Scholar
• Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr. Opin. Immunol. 21(3), 314–320 (2009).
   PubMed Web of Science ®Google Scholar
• Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122(4), 303–309 (1970).
   PubMed Web of Science ®Google Scholar
• Frey SE, Couch RB, Tacket CO et al. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med. 346(17), 1265–1274 (2002).
   PubMed Web of Science ®Google Scholar
• Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. J. Infect. Dis. 189(8), 1401–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37(2), 251–271 (2003).
   PubMed Web of Science ®Google Scholar
• Umlauf BJ, Ovsyannikova IG, Haralambieva IH et al. Correlations between vaccinia-specific immune responses within a cohort of armed forces members. Viral Immunol. 24(5), 415–420 (2011).
   PubMed Web of Science ®Google Scholar
• Moss B. Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239(1), 8–26 (2011).
   PubMed Web of Science ®Google Scholar
• Talbot TR, Bredenberg HK, Smith M, Lafleur BJ, Boyd A, Edwards KM. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA 289(24), 3290–3294 (2003).
   PubMed Web of Science ®Google Scholar
• Reif DM, Mckinney BA, Motsinger AA et al. Genetic basis for adverse events after smallpox vaccination. J. Infect. Dis. 198(1), 16–22 (2008).
   PubMed Web of Science ®Google Scholar
• Halsell JS, Riddle JR, Atwood JE et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289, 3283–3289 (2003).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Klinman D, Berzofsky JA. Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J. Immunol. 177(9), 6336–6343 (2006).
   PubMed Web of Science ®Google Scholar
• Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172(10), 6265–6271 (2004).
   PubMed Web of Science ®Google Scholar
• Smith GL, Benfield CT, Maluquer De Motes C et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J. Gen. Virol. 94(Pt 11), 2367–2392 (2013).
   PubMedGoogle Scholar
• Epperson ML, Lee CA, Fremont DH. Subversion of cytokine networks by virally encoded decoy receptors. Immunol. Rev. 250(1), 199–215 (2012).
   PubMedGoogle Scholar
• Bahar MW, Graham SC, Chen RA et al. How vaccinia virus has evolved to subvert the host immune response. J. Struct. Biol. 175(2), 127–134 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen JI, Hohman P, Fulton R et al. Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine. J. Infect. Dis. 201(8), 1183–1191 (2010).
   PubMed Web of Science ®Google Scholar
• Combadiere B, Boissonnas A, Carcelain G et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J. Exp. Med. 199(11), 1585–1593 (2004).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Cruz J, Demkowicz WE Jr, Rothman AL, McClain DJ. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. J. Infect. Dis. 185(11), 1657–1659 (2002).
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Cruz J et al. Dose-related effects of smallpox vaccine. N. Engl. J. Med. 346(17), 1275–1280 (2002).
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9(9), 1131–1137 (2003).
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Ovsyannikova IG, Dhiman N et al. Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African–Americans. J. Infect. Dis. 204(3), 433–441 (2011).
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Oberg AL, Dhiman N et al. High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination. J. Infect. Dis. 206(10), 1512–1520 (2012).
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Shane Pankratz V, Poland GA. Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Hum. Immunol. 74(10), 1263–1266 (2013).
   PubMed Web of Science ®Google Scholar
• Judkowski V, Bunying A, Ge F et al. GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination. PLoS ONE 6(9), e24091 (2011).
   PubMed Web of Science ®Google Scholar
• Kennedy RB, Ovsyannikova IG, Shane PV, Haralambieva IH, Vierkant RA, Poland GA. Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients. Hum. Genet. 131(9), 1403–1421 (2012).
   PubMed Web of Science ®Google Scholar
• McKinney BA, Reif DM, Rock MT et al. Cytokine expression patterns associated with systemic adverse events following smallpox immunization. J. Infect. Dis. 194(4), 444–453 (2006).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine. J. Infect. Dis. 203(11), 1546–1555 (2011).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Haralambieva IH, Kennedy RB et al. Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene 510, 59–65 (2012).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Haralambieva IH, Kennedy RB, O’Byrne MM, Pankratz VS, Poland GA. Genetic variation in IL18R1 and IL18 genes and inteferon gamma ELISPOT response to smallpox vaccination: an unexpected relationship. J. Infect. Dis. 208(9), 1422–1430 (2013).
   PubMed Web of Science ®Google Scholar
• Reif DM, Motsinger-Reif AA, McKinney BA, Rock MT, Crowe JE Jr , Moore JH. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun. 10(2), 112–119 (2009).
   PubMed Web of Science ®Google Scholar
• WHO. Summary report on first, second, and third generation smallpox vaccines (2013). www.who.int/immunization/sage/meetings/2013/november/2_Smallpox_vaccine_review_updated_11_10_13.pdf
   Google Scholar
• Kretzschmar M, Wallinga J, Teunis P, Xing S, Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. 3(8), e272 (2006).
   PubMed Web of Science ®Google Scholar
• Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Devel. Ther. 4, 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2), S31–S44 (2004).
   PubMedGoogle Scholar
• Frey SE, Newman FK, Kennedy JS et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27(10), 1637–1644 (2009).
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Johnson C, Marbury TC et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23(25), 3301–3309 (2005).
   PubMed Web of Science ®Google Scholar
• Muller U, Steinhoff U, Reis LF et al. Functional role of type I and type II interferons in antiviral defense. Science 264(5167), 1918–1921 (1994).
   PubMed Web of Science ®Google Scholar
• Harris N, Buller RM, Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69(2), 910–915 (1995).
   PubMed Web of Science ®Google Scholar
• Karupiah G, Xie QW, Buller ML, Nathan C, Duarte C, Macmicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261, 1445–1448 (1993).
   PubMed Web of Science ®Google Scholar
• Cantin E, Tanamachi B, Openshaw H. Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J. Virol. 73(4), 3418–3423 (1999).
   PubMed Web of Science ®Google Scholar
• Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259(5102), 1739–1742 (1993).
   PubMed Web of Science ®Google Scholar
• Fiette L, Aubert C, Muller U et al. Theiler’s virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J. Exper. Med. 181(6), 2069–2076 (1995).
   PubMed Web of Science ®Google Scholar
• Finke D, Brinckmann UG, Ter Meulen V, Liebert UG. Gamma interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis. J. Virol. 69, 5469–5474 (1995).
   PubMed Web of Science ®Google Scholar
• Huang S, Hendriks W, Althage A et al. Immune response in mice that lack the interferon-gamma receptor. Science 259(5102), 1742–1745 (1993).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Earl P, Dzutsev A et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100(16), 9458–9463 (2003).
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hanifin JM, Mori M, Koudelka CW, Slifka MK. Antiviral immunity following smallpox virus infection: a case–control study. J. Virol. 84(24), 12754–12760 (2010).
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171(10), 4969–4973 (2003).
   PubMed Web of Science ®Google Scholar
• Kennedy RB, Ovsyannikova IG, Pankratz VS et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum. Genet. 131(9), 1433–1451 (2012).
   PubMed Web of Science ®Google Scholar
• Stanley SL Jr , Frey SE, Taillon-Miller P et al. The immunogenetics of smallpox vaccination. J. Infect. Dis. 196(2), 212–219 (2007).
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Quesada JR, Talpaz M et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J. Clin. Oncol. 4(7), 1101–1109 (1986).
   PubMed Web of Science ®Google Scholar
• Migueles SA, Sabbaghian MS, Shupert WL et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97(6), 2709–2714 (2000).
   PubMed Web of Science ®Google Scholar
• Pelak K, Goldstein DB, Walley NM et al. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201(8), 1141–1149 (2010).
   PubMed Web of Science ®Google Scholar
• Tang J, Wilson CM, Meleth S et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 16(17), 2275–2284 (2002).
   PubMed Web of Science ®Google Scholar
• Kaslow RA, Rivers C, Tang J et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J. Virol. 75(18), 8681–8689 (2001).
   PubMed Web of Science ®Google Scholar
• Murphy K. Janeway’s Immunobiology (8th Edition). Garland Science, NY, USA (2011).
   Google Scholar
• Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a Phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunother. 38(2), 119–126 (1994).
   PubMed Web of Science ®Google Scholar
• Kurilla MG, Swaminathan S, Welsh RM, Kieff E, Brutkiewicz RR. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J. Virol. 67(12), 7623–7628 (1993).
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 131(3), 1531–1538 (1983).
   PubMed Web of Science ®Google Scholar
• Patera AC, Pesnicak L, Bertin J, Cohen JI. Interleukin 17 modulates the immune response to vaccinia virus infection. Virology 299(1), 56–63 (2002).
   PubMed Web of Science ®Google Scholar
• Yao C, Sakata D, Esaki Y et al. Prostaglandin E2–EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15(6), 633–640 (2009).
   PubMed Web of Science ®Google Scholar
• Bankhurst AD. The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol. 7(2), 85–91 (1982).
   PubMedGoogle Scholar
• Howell MD, Gallo RL, Boguniewicz M et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 24(3), 341–348 (2006).
   PubMed Web of Science ®Google Scholar
• Reed JL, Scott DE, Bray M. Eczema vaccinatum. Clin. Infect. Dis. 54(6), 832–840 (2012).
   PubMed Web of Science ®Google Scholar
• Oyoshi MK, Elkhal A, Kumar L et al. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc. Natl. Acad. Sci. USA 106(35), 14954–14959 (2009).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Tomimori Y, Yumoto K et al. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exper. Med. 206(6), 1219–1225 (2009).
   PubMed Web of Science ®Google Scholar
• Kohyama S, Ohno S, Isoda A et al. IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J. Immunol. 179(6), 3917–3925 (2007).
   PubMed Web of Science ®Google Scholar
• Pessi T, Karjalainen J, Hulkkonen J, Nieminen MM, Hurme M. A common IL-1 complex haplotype is associated with an increased risk of atopy. J. Med. Genet. 40(5), e66 (2003).
   PubMed Web of Science ®Google Scholar
• Smith AJ, Keen LJ, Billingham MJ et al. Extended haplotypes and linkage disequilibrium in the IL1R1–IL1A–IL1B–IL1RN gene cluster: association with knee osteoarthritis. Genes Immun. 5(6), 451–460 (2004).
   PubMed Web of Science ®Google Scholar
• Timms AE, Crane AM, Sims AM et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am. J. Hum. Genet. 75(4), 587–595 (2004).
   PubMed Web of Science ®Google Scholar
• Lim BK, Choe SC, Shin JO et al. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105(11), 1278–1281 (2002).
   PubMed Web of Science ®Google Scholar
• Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J. Immunol. 151(3), 1682–1690 (1993).
   PubMed Web of Science ®Google Scholar
• Jin P, Wang E. Polymorphism in clinical immunology – from HLA typing to immunogenetic profiling. J. Transl. Med. 1(1), 8 (2003).
   PubMedGoogle Scholar
• Attar RM, Caamano J, Carrasco D et al. Genetic approaches to study Rel/NF-kappa B/I kappa B function in mice. Semin. Cancer Biol. 8(2), 93–101 (1997).
   PubMed Web of Science ®Google Scholar
• Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. Curr. Opin. Immunol. 12(1), 52–58 (2000).
   PubMed Web of Science ®Google Scholar
• Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl. Acad. Sci. USA 101(23), 8815–8820 (2004).
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12(1), 53–72 (2001).
   PubMed Web of Science ®Google Scholar
• Tanaka-Kataoka M, Kunikata T, Takayama S et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 11(8), 593–599 (1999).
   PubMed Web of Science ®Google Scholar
• Wang Y, Chaudhri G, Jackson RJ, Karupiah G. IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J. Immunol. 183(5), 3324–3331 (2009).
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Ramirez JC, Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol. 84(Pt 8), 1961–1972 (2003).
   PubMedGoogle Scholar
• Reading PC, Smith GL. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J. Virol. 77(18), 9960–9968 (2003).
   PubMed Web of Science ®Google Scholar
• Fuse K, Chan G, Liu Y et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112(15), 2276–2285 (2005).
   PubMed Web of Science ®Google Scholar
• Arness MK, Eckart RE, Love SS et al. Myopericarditis following smallpox vaccination. Am. J. Epidemiology 160(7), 642–651 (2004).
   PubMed Web of Science ®Google Scholar
• Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol. Today 14(10), 506–512 (1993).
   PubMedGoogle Scholar
• Yao Z, Painter SL, Fanslow WC et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155(12), 5483–5486 (1995).
   PubMed Web of Science ®Google Scholar
• Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75(3), 1205–1210 (2001).
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17, 701–738 (1999).
   PubMed Web of Science ®Google Scholar
• Smith GL, McFadden G. Smallpox: anything to declare? Nat. Rev. Immunol. 2(7), 521–527 (2002).
   PubMed Web of Science ®Google Scholar
• Reif DM, McKinney BA, Motsinger AA et al. Genetic basis for adverse events after smallpox vaccination. J. Infect. Dis. 198, 1–7 (2008).
   PubMed Web of Science ®Google Scholar
• Ouyang P, Rakus K, Van Beurden SJ et al. IL-10 encoded by viruses: a remarkable example of independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral genome. J. Gen. Virol. 95(Pt 2), 245–262 (2014).
   PubMedGoogle Scholar
• Walline CC, Sehra S, Fisher AJ et al. Allergic airway disease in mice alters T and B cell responses during an acute respiratory poxvirus infection. PLoS ONE 8(4), e62222 (2013).
   PubMed Web of Science ®Google Scholar
• Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur. J. Immunol. 29(9), 2658–2665 (1999).
   PubMed Web of Science ®Google Scholar
• Moore KW, De Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. 19, 683–765 (2001).
   PubMed Web of Science ®Google Scholar
• Sorkness RL, Gern JE, Grindle KA et al. Persistence of viral RNA in 2 rat strains differing in susceptibility to postbronchiolitis airway dysfunction. J. Allergy Clin. Immunol. 110(4), 607–609 (2002).
   PubMed Web of Science ®Google Scholar
• Liu L, Xu Z, Fuhlbrigge RC, Pena-Cruz V, Lieberman J, Kupper TS. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J. Virol. 79(12), 7363–7370 (2005).
   PubMed Web of Science ®Google Scholar
• Malek TR. T helper cells, IL-2 and the generation of cytotoxic T-cell responses. Trends Immunol. 23(10), 465–467 (2002).
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exper. Med. 170(3), 827–845 (1989).
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol. 16, 495–521 (1998).
   PubMed Web of Science ®Google Scholar
• Beagley KW, Eldridge JH, Lee F et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J. Exper. Med. 169(6), 2133–2148 (1989).
   PubMed Web of Science ®Google Scholar
• Vollmar J, Arndtz N, Eckl KM et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24(12), 2065–2070 (2006).
   PubMed Web of Science ®Google Scholar
• Meseda CA, Weir JP. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox. Future Microbiol. 5(9), 1367–1382 (2010).
   PubMed Web of Science ®Google Scholar